{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAPEOX", "query": { "intervention": "CAPEOX" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAPEOX&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T00:42:22.648Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05855200", "title": "Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colonic Neoplasms", "Neoplasms, Colon" ], "interventions": [ { "name": "Dostarlimab", "type": "BIOLOGICAL" }, { "name": "CAPEOX", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 892, "start_date": "2023-08-01", "completion_date": "2031-03-27", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-09-08T00:42:22.648Z", "location_count": 49, "location_summary": "Tucson, Arizona • Los Angeles, California • New Haven, Connecticut + 31 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Deerfield Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05855200" }, { "nct_id": "NCT05158621", "title": "A Screening Study Targeting Tumor-specific Antigens", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Colorectal Cancer", "Stage II/III Colon Cancer" ], "interventions": [ { "name": "blood collection for research (next generation sequencing [NGS])", "type": "PROCEDURE" }, { "name": "blood collection for research (HLA typing)", "type": "PROCEDURE" }, { "name": "blood collection for research (circulating tumor DNA [ctDNA])", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Gritstone bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 22, "start_date": "2021-12-14", "completion_date": "2022-08-15", "has_results": false, "last_update_posted_date": "2022-10-18", "last_synced_at": "2026-09-08T00:42:22.648Z", "location_count": 6, "location_summary": "Miami, Florida • Tamarac, Florida • East Brunswick, New Jersey + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Tamarac", "state": "Florida" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05158621" }, { "nct_id": "NCT04703101", "title": "Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Rectal Carcinoma", "Rectal Adenocarcinoma", "Stage II Rectal Cancer AJCC v8", "Stage IIA Rectal Cancer AJCC v8", "Stage IIB Rectal Cancer AJCC v8", "Stage IIC Rectal Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Stage IIIA Rectal Cancer AJCC v8", "Stage IIIB Rectal Cancer AJCC v8", "Stage IIIC Rectal Cancer AJCC v8" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Surveillance", "type": "BEHAVIORAL" }, { "name": "Total Mesorectal Excision", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER", "BEHAVIORAL", "PROCEDURE" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-02-11", "completion_date": "2027-10-15", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-09-08T00:42:22.648Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04703101" }, { "nct_id": "NCT01167725", "title": "Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "FOLFIRI regimen", "type": "DRUG" }, { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "mitomycin C", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 340, "start_date": "2010-08", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-09-08T00:42:22.648Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Winston-Salem, North Carolina", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01167725" }, { "nct_id": "NCT02008656", "title": "Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "Oxaliplatin (OXAL)", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Capecitabine (Xeloda®)", "type": "DRUG" }, { "name": "intensity modulated radiotherapy (IMRT)", "type": "RADIATION" }, { "name": "Quality of Life Questionnaires", "type": "BEHAVIORAL" }, { "name": "DRE-Endoscopy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "BEHAVIORAL", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 358, "start_date": "2013-11", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-08T00:42:22.648Z", "location_count": 26, "location_summary": "Irvine, California • Orange, California • San Francisco, California + 22 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02008656" }, { "nct_id": "NCT00680901", "title": "LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms, Gastrointestinal Tract" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 545, "start_date": "2008-06-04", "completion_date": "2024-10-03", "has_results": true, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-09-08T00:42:22.648Z", "location_count": 10, "location_summary": "Alhambra, California • Fullerton, California • La Verne, California + 7 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Verne", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Oxnard", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00680901" }, { "nct_id": "NCT07167446", "title": "Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients", "Metastatic Colorectal Cancer (CRC)", "Peripheral Neuropathy Due to Chemotherapy" ], "interventions": [ { "name": "Cannabidiol (CBD)", "type": "DRUG" }, { "name": "oxaliplatin-based chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-10-14", "completion_date": "2028-09-07", "has_results": false, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-09-08T00:42:22.648Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07167446" }, { "nct_id": "NCT06728072", "title": "Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "CRC" ], "interventions": [ { "name": "Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2025-03-07", "completion_date": "2035-07-01", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-08T00:42:22.648Z", "location_count": 2, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06728072" }, { "nct_id": "NCT01280643", "title": "Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "mutation analysis", "type": "GENETIC" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "nucleic acid sequencing", "type": "GENETIC" }, { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "DNA analysis", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "GENETIC", "OTHER" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2010-03", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2021-03-15", "last_synced_at": "2026-09-08T00:42:22.648Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01280643" }, { "nct_id": "NCT06328738", "title": "ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER2 Positive Solid Tumors", "HER2 Amplification", "Colorectal Cancer" ], "interventions": [ { "name": "ELVN-002", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enliven Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2024-05-30", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-09-08T00:42:22.648Z", "location_count": 3, "location_summary": "Plantation, Florida • St Louis, Missouri • Fairfax, Virginia", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06328738" } ] }